Association between interleukin-4 gene intron 3 VNTR polymorphism and cancer risk

Cancer Cell International

Suzhan Zhang²  Hailong Chen²  Jinan Shi¹  Chi Pan²  Yin Duan² 

[1] Department of Medical Oncology, Zhejiang Hospital, Hangzhou, Zhejiang Province, PR China;Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, PR China

关键词: Meta-analysis;    Polymorphism;    Interleukin-4;    Cancer;   

Others  :  1121616
DOI  :  10.1186/s12935-014-0131-7

 received in 2014-08-10, accepted in 2014-11-17,  发布年份 2014

【 摘 要 】

Background

Interleukin-4(IL-4) is a critical inflammatory cytokine and has been involved in pathogenesis of cancer. To date, several studies have investigated the association between IL-4 intron 3 variable number of tandem repeats (VNTR) polymorphism and cancer risk in humans; however, the results remain controversial. We performed this meta-analysis to find a more conclusive association between this polymorphism and cancer risk.

Methods

Eight eligible case–control studies were identified through searching electronic databases, including 1583 cases and 1638 controls. Odds ratio (OR) and corresponding 95% confidence interval (CI) were used to estimate the strength of the association.

Results

The results of overall analyses indicated that the variant RP2 allele was associated with a decreased cancer risk compared with the RP1 allele (RP2/RP2 vs. RP1/RP1, OR = 0.64, 95% CI = 0.44-0.94; RP2/RP2 vs. RP1/RP1 + RP1/RP2, OR = 0.75, 95% CI = 0.60-0.92; RP2 vs. RP1, OR = 0.72, 95% CI = 0.56-0.92). In subgroup analyses stratified by ethnicity, there was evidence in the Asian population for an association between this polymorphism and cancer risk (RP2/RP2 vs. RP1/RP1 + RP1/RP2, OR = 0.79, 95% CI = 0.63-0.99; RP2 vs. RP1, OR = 0.77, 95% CI = 0.61-0.97).

Conclusions

IL-4 intron 3 VNTR polymorphism could influence the risk of human cancer. Due to the limitations of this meta-analysis, further well-designed and functional researches should be performed to validate our results.

【 授权许可】

   
2014 Duan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 2001, 411(6835):366-374.
• [2]Bredberg A: Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer 2011, 117(3):440-445.
• [3]Wang S, Liu Z, Wang L, Zhang X: NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009, 6(5):327-334.
• [4]Kuper H, Adami HO, Trichopoulos D: Infections as a major preventable cause of human cancer. J Intern Med 2000, 248(3):171-183.
• [5]Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D’Alfonso S: Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999, 1(1):3-19.
• [6]Olver S, Apte S, Baz A, Kienzle N: The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? Tissue Antigens 2007, 69(4):293-298.
• [7]Swain SL, Weinberg AD, English M, Huston G: IL-4 directs the development of Th2-like helper effectors. J Immunol 1990, 145(11):3796-3806.
• [8]Toi M, Bicknell R, Harris AL: Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992, 52(2):275-279.
• [9]Yu SJ, Kim HS, Cho SW, Sohn J: IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp Mol Med 2004, 36(4):372-379.
• [10]Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL: Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 1996, 2(1):127-135.
• [11]Manchanda P, Sharma SC, Das SN: Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma. Oral Dis 2006, 12(5):455-462.
• [12]Agarwal A, Rani M, Saha GK, Valarmathi TM, Bahadur S, Mohanti BK, Das SN: Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Investig 2003, 32(1–2):17-30.
• [13]Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T: Serum cytokine levels in patients with oral mucous membrane disorders. J Oral Pathol Med 1991, 20(6):275-279.
• [14]Liang J, Li Y, Liu X, Xu X, Zhao Y: Relationship between cytokine levels and clinical classification of gastric cancer. Asian Pac J Cancer Prev 2011, 12(7):1803-1806.
• [15]Goto T, Nishizono A, Fujioka T, Ikewaki J, Mifune K, Nasu M: Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Infect Immun 1999, 67(5):2531-2539.
• [16]Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E: Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 2008, 44(12):1093-1099.
• [17]Rosenwasser LJ, Klemm DJ, Dresback JK, Inamura H, Mascali JJ, Klinnert M, Borish L: Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 1995, 25(Suppl 2):74-78. discussion 95–76
• [18]Mout R, Willemze R, Landegent JE: Repeat polymorphisms in the interleukin-4 gene (IL4). Nucleic Acids Res 1991, 19(13):3763.
• [19]Nakashima H, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y, Otsuka T, Harada M: Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 2002, 3(2):107-109.
• [20]Breslow NE, Day NE: Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.IARC Sci Publ 1987, (82):1–406.
• [21]Haber M: Exact significance levels of goodness-of-fit tests for the Hardy-Weinberg equilibrium. Hum Hered 1981, 31(3):161-166.
• [22]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560.
• [23]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [24]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [25]Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53(11):1119-1129.
• [26]Tsai FJ, Chang CH, Chen CC, Hsia TC, Chen HY, Chen WC: Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder. BJU Int 2005, 95(3):432-435.
• [27]Tsai MH, Chen WC, Tsai CH, Hang LW, Tsai FJ: Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal 2005, 19(3):93-98.
• [28]Lai KC, Chen WC, Jeng LB, Li SY, Chou MC, Tsai FJ: Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur J Surg Oncol 2005, 31(10):1135-1140.
• [29]Kesarwani P, Ahirwar DK, Mandhani A, Mittal RD: Association between −174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 2008, 27(9):505-510.
• [30]Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK: Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncol Res 2009, 17(8):367-372.
• [31]Shekari M, Kordi-Tamandani DM, MalekZadeh K, Sobti RC, Karimi S, Suri V: Effect of anti-inflammatory (IL-4, IL-10) cytokine genes in relation to risk of cervical carcinoma. Am J Clin Oncol 2012, 35(6):514-519.
• [32]Yang CM, Chen HC, Hou YY, Lee MC, Liou HH, Huang SJ, Yen LM, Eng DM, Hsieh YD, Ger LP: A high IL-4 production diplotype is associated with an increased risk but better prognosis of oral and pharyngeal carcinomas. Arch Oral Biol 2014, 59(1):35-46.
• [33]Bozdogan ST, Erol B, Dursun A, Bozdogan G, Donmez I, Mungan NA, Seydaoglu G: The IL-1RN and IL-4 gene polymorphisms are potential genetic markers of susceptibility to bladder cancer: a case–control study.World J Urol 2014, [Epub ahead of print].
• [34]Zhang H, Xu Y, Zhang Z, Liu R, Ma B: Association between COX-2 rs2745557 polymorphism and prostate cancer risk: a systematic review and meta-analysis. BMC Immunol 2012, 13:14. BioMed Central Full Text
• [35]Zhang H, Qi C, Li L, Luo F, Xu Y: Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res 2013, 32(1):56. BioMed Central Full Text
• [36]Abaza MS, Bahman AM, Al-Attiyah RJ, Kollamparambil AM: Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. Tumour Biol 2012, 33(6):1951-1972.
• [37]Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Banas H, Morgado S, Casado JG, Solana R, Tarazona R: Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 2013, 61(3):885-891.
• [38]Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE: Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 2001, 8(2):116-122.
• [39]Lathers DM, Young MR: Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 2004, 25(5):220-228.
• [40]Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT: Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999, 21(3):339-359.
• [41]Mellgren K, Hedegaard CJ, Schmiegelow K, Muller K: Plasma cytokine profiles at diagnosis in pediatric patients with non-hodgkin lymphoma. J Pediatr Hematol Oncol 2012, 34(4):271-275.
• [42]Pan XF, Wen Y, Loh M, Wen YY, Yang SJ, Zhao ZM, Tian Z, Huang H, Lan H, Chen F, Soong R, Yang CX: Interleukin-4 and −8 gene polymorphisms and risk of gastric cancer in a population in Southwestern China. Asian Pac J Cancer Prev 2014, 15(7):2951-2957.
• [43]Jin T, Li X, Zhang J, Wang H, Geng T, Li G, Gao G, Chen C: Genetic association between selected cytokine genes and glioblastoma in the Han Chinese population. BMC Cancer 2013, 13:236. BioMed Central Full Text
• [44]Monroy CM, Cortes AC, Lopez MS, D’Amelio AM Jr, Etzel CJ, Younes A, Strom SS, El-Zein RA: Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 2011, 50(1):36-46.
• [45]Olson SH, Orlow I, Simon J, Tommasi D, Roy P, Bayuga S, Ludwig E, Zauber AG, Kurtz RC: Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev 2007, 31(5):345-351.
• [46]Zhenzhen L, Xianghua L, Qingwei W, Zhan G, Ning S: Three common polymorphisms in the IL-4 gene and cancer risk: a meta-analysis involving 5,392 cases and 6,930 controls. Tumour Biol 2013, 34(4):2215-2224.